What caused the recent price surge of 2591.HK?

The recent 19% increase in Guangzhou Innogen's stock price was driven by substantial trading volume and possibly speculative trading interest within the Biotechnology sector.

Is Guangzhou Innogen profitable?

Currently, Guangzhou Innogen is not profitable, evidenced by a negative earnings per share (EPS) of -0.54 and a PE ratio of -70.96. The company is focusing on research and development in biotechnology.

What is the stock's recent trading volume compared to its average?

On December 10, 2025, the stock traded 6,206,710 shares, significantly above its average daily volume of 522,903 shares, indicating heightened market activity.

What are Guangzhou Innogen’s future prospects?

Guangzhou Innogen's future potential lies in its innovative GLP-1 receptor agonists for diabetes, with Meyka AI forecasting a potential price target of HK$48.21 for the coming month.

How does 2591.HK compare within its sector?

Despite unprofitability, 2591.HK shows strong liquidity and a unique product portfolio within the Biotechnology sector, suggesting potential for growth if strategic goals are met.

HK Stocks

Guangzhou Innogen Pharmaceutl Grp Co Ltd (2591.HK) Surges 19% Amid High Trading Volume

ByHuzaifa Zahoor December 11, 2025December 11, 2025

Guangzhou Innogen Pharmaceutl Grp Co Ltd (2591.HK) captivated Hong Kong investors as its stock price skyrocketed by 19% in a single day, closing at HK$38.32. This surge in value was propelled by an extraordinary trading volume of 6.2 million shares—nearly 12 times its average.